A population-based survey of Chronic REnal Disease in Turkey-the CREDIT study

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1862-1871

  Süleymanlar, Gltekin ^a   Uta, Cengiz ^b   Arinsoy, Turgay ^c   Ate, Kenan ^d   Altun, Blent ^e   Altiparmak, Mehmet Riza ^f   Ecder, Tevfik ^g   Yilmaz, Mehmet Emin ^h   Amsari, Taner ⁱ   Bai, Ali ^j   Serdengeti, Kamil ^f  

^a AKDENIZ UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e HACETTEPE UNIVERSITY   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

ⁱ DOKUZ EYLUL UNIVERSITY   (Turkey)

^j EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

chronic kidney disease; epidemiology and outcomes; risk factors

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERTENSION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC); URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH SURVEYS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TURKEY;

EID: 79951753692     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq656     Document Type: Article

References (47)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065. (Pubitemid 37413751)
2. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002; 39: S1-S266.
3. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
4. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2007. Amsterdam, the Netherlands: Academic Medical Center, Department of Medical Informatics, 2009; http://www.era-edta-reg.org/index.jsp? p=annrep.
5. U.S. Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009; http:// www.usrds.org/atlas.htm.
6. Erek E, Suleymanlar G, Serdengecti K. Nephrology, dialysis and transplantation in Turkey. Nephrol Dial Transplant 2002; 17: 2087-2093. (Pubitemid 35452500)
7. Serdengeçti K, Süleymanlar G, Altiparmak M et al. Registry of the Nephrology Dialysis and Transplantation in Turkey (Registry-2008). Istanbul: Published by the Turkish Society of Nephrology, 2009.
8. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
9. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117.
10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
11. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816. (Pubitemid 39473602)
12. Atthobari J, Asselbergs FW, Boersma C et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther 2006; 28: 432-444. (Pubitemid 43783432)
13. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
14. Prime Minister Republic of Turkey, Turkish Statistical Institute, www. turkstat.gov.tr.
15. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12. (Pubitemid 36043346)
16. Carter JL, Tomson CR, Stevens PE et al. Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. Nephrol Dial Transplant 2006; 21: 3031-3037. (Pubitemid 44567071)
17. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
18. Gansevoort RT, Verhave JC, Hillege HL et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005; S28-S35.
19. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21: 1-6. (Pubitemid 43194325)
20. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284. (Pubitemid 44141918)
21. Cirillo M, Laurenzi M, Mancini M et al. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int 2006; 70: 800-806. (Pubitemid 44215358)
22. Nitsch D, Felber Dietrich D, von Eckardstein A et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21: 935-944.
23. Viktorsdottir O, Palsson R, Andresdottir MB et al. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant 2005; 20: 1799-1807. (Pubitemid 41222591)
24. Singh NP, Ingle GK, Saini VK et al. Prevalence of low glomerular filtration rate, proteinuria and associated risk factors in North India using Cockcroft-Gault and Modification of Diet in Renal Disease equation: an observational, cross-sectional study. BMC Nephrol 2009; 10: 4.
25. Chen J, Wildman RP, Gu D et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int 2005; 68: 2837-2845. (Pubitemid 43251031)
26. Eknoyan G, Hostetter T, Bakris GL et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42: 617-622. (Pubitemid 37187362)
27. Lameire N, van Biesen W. The pattern of referral of patients with end-stage renal disease to the nephrologist-a European survey. Nephrol Dial Transplant 1999; 14: 16-23. (Pubitemid 29462210)
28. Iseki K. The Okinawa screening program. J Am Soc Nephrol 2003; 14: S127-S130. (Pubitemid 36750507)
29. Ishani A, Grandits GA, Grimm RH et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17: 1444-1452. (Pubitemid 43673426)
30. Gansevoort RT, Bakker SJ, de Jong PE. Early detection of progressive chronic kidney disease: is it feasible? J Am Soc Nephrol 2006; 17: 1218-1220. (Pubitemid 43673400)
31. Hallan SI, Ritz E, Lydersen S et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-1077.
32. McCullough PA, Jurkovitz CT, Pergola PE et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167: 1122-1129. (Pubitemid 46919814)
33. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10. (Pubitemid 32429589)
34. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-137.
35. Tokgozoglu L, Baris Kaya E. Atherosclerotic vascular disease and risk factors in Turkey: from past to present. J Atheroscler Thromb 2008; 15: 286-291.
36. Onat A, Ugur M, Tuncer M et al. Age at death in the Turkish Adult Risk Factor Study: temporal trend and regional distribution at 56,700 person-years' follow-up. Türk Kardiyol Dern Ars 2009; 37: 155-160.
37. Satman I, Yilmaz T, Sengul A et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diab Care 2002; 25: 1551-1556. (Pubitemid 41071110)
38. Onat A, Hergenc G, Uyarel H et al. Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadolu Kardiyol Derg 2006; 6: 314-321. (Pubitemid 46131050)
39. Jones CA, Francis ME, Eberhardt MS et al. Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-459. (Pubitemid 34194620)
40. Altun B, Arici M, Nergizoglu G et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005; 23: 1817-1823. (Pubitemid 41830421)
41. Arici M, Turgan C, Altun B et al. Hypertension incidence in Turkey (HinT): a population-based study. J Hypertens 2010; 28: 240-244.
42. Ejerblad E, Fored CM, Lindblad P et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702. (Pubitemid 43794672)
43. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140. (Pubitemid 41716445)
44. Oguz A, Temizhan A, Abaci A et al. Obesity and abdominal obesity; an alarming challenge for cardio-metabolic risk in Turkish adults. Anadolu Kardiyol Derg 2008; 8: 401-406.
45. Sanisoglu SY, Oktenli C, Hasimi A et al. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6: 92.
46. Kim S, Lim CS, Han DC et al. The prevalence of chronic kidney disease (CKD) and the associated factors to CKD in urban Korea: a population-based cross-sectional epidemiologic study. J Korean Med Sci 2009; 24: S11-S21.
47. Nygaard H, Naik M, Ruths S et al. Clinically important renal impairment in various groups of old persons. Scand J Prim Health Care 2004; 22: 152-156 (Pubitemid 39281027)